

CUTANEOUS LYMPHOMA FOUNDATION, INC.

AUDITED FINANCIAL STATEMENTS

FOR THE YEARS ENDED
JUNE 30, 2024 AND 2023

INDEX

	<u>PAGE</u>
INDEPENDENT AUDITOR'S REPORT	1 - 2
STATEMENTS OF FINANCIAL POSITION	3
STATEMENTS OF ACTIVITIES	4 - 5
STATEMENTS OF CASH FLOWS	6
SCHEDULE OF FUNCTIONAL EXPENSES	7
NOTES TO FINANCIAL STATEMENTS	8 - 12

O'BRIEN, RIVAMONTE, SLATE & SCHULTE, P.C.

CERTIFIED PUBLIC ACCOUNTANTS
25800 NORTHWESTERN HIGHWAY #1100
SOUTHFIELD, MICHIGAN 48075

MEMBERS
THE AMERICAN INSTITUTE OF
CERTIFIED PUBLIC ACCOUNTANTS

(248) 353-2800
FAX (248) 353-2737
www.ors-cpa.com

MEMBERS
THE MICHIGAN ASSOCIATION OF
CERTIFIED PUBLIC ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors
Cutaneous Lymphoma Foundation, Inc.

OPINION

We have audited the accompanying statement of financial position of Cutaneous Lymphoma Foundation, Inc. (a 501 (c)(3) Michigan nonprofit Corporation) as of June 30, 2024 and 2023, and the related statements of activities, cash flows and functional expenses for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Cutaneous Lymphoma Foundation, Inc. as of June 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

BASIS FOR OPINION

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Cutaneous Lymphoma Foundation, Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

RESPONSIBILITIES OF MANAGEMENT FOR THE FINANCIAL STATEMENTS

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Cutaneous Lymphoma Foundation Inc's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

-Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

-Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Cutaneous Lymphoma Foundation Inc's internal control. Accordingly, no such opinion is expressed.

-Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

-Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Cutaneous Lymphoma Foundation Inc's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

O'Brien, Rivamonte, Slate & Schulte, P.C.

Southfield, Michigan

October 8, 2024

CUTANEOUS LYMPHOMA FOUNDATION, INC.
STATEMENTS OF FINANCIAL POSITION
AS OF JUNE 30, 2024 and 2023

ASSETS

	<u>2024</u>	<u>2023</u>
CURRENT ASSETS		
Cash and cash equivalents	\$ 752,007	\$ 958,862
Certificate of deposits	239,480	229,927
Promises to give	126,155	103,000
Total current assets	<u>1,117,642</u>	<u>1,291,789</u>
FIXED ASSETS		
Property and equipment	150,951	150,951
Right of Use Asset	57,624	75,961
Less: Accumulated depreciation	134,940	115,914
Total Fixed Assets	<u>73,635</u>	<u>110,998</u>
OTHER ASSETS		
Prepaid expenses	10,973	1,670
Security deposit	1,706	1,706
Total other assets	<u>12,679</u>	<u>3,376</u>
TOTAL ASSETS	<u>\$ 1,203,956</u>	<u>\$ 1,406,163</u>
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable	\$ 17,243	\$ 21,627
Lease payable - current	19,069	18,337
Total current liabilities	<u>36,312</u>	<u>39,964</u>
LONG TERM LIABILITIES		
Lease payable - long term	38,555	57,624
Total long term liabilities	<u>38,555</u>	<u>57,624</u>
Total liabilities	74,867	97,588
NET ASSETS		
Net assets without restrictions	595,403	821,556
Net assets with restrictions	533,686	487,019
Total net assets	<u>1,129,089</u>	<u>1,308,575</u>
TOTAL LIABILITIES AND NET ASSETS	<u>\$ 1,203,956</u>	<u>\$ 1,406,163</u>

See independent auditor's report and accompanying notes to financial statements.

**CUTANEOUS LYMPHOMA FOUNDATION, INC.
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2024**

	Net assets without restrictions	Net assets with restrictions	Total
SUPPORT AND REVENUE			
Contributions and grants	\$ 228,896	\$ 488,470	\$ 717,366
Interest income	28,772	0	28,772
TOTAL SUPPORT AND REVENUE	257,668	488,470	746,138
NET ASSETS RELEASED FROM RESTRICTIONS	441,803	(441,803)	0
	699,471	46,667	746,138
FUNCTIONAL EXPENSES			
Program	759,566	0	759,566
Management and general	122,440	0	122,440
Fundraising	43,618	0	43,618
TOTAL FUNCTIONAL EXPENSES	925,624	0	925,624
CHANGE IN NET ASSETS	(226,153)	46,667	(179,486)
NET ASSETS - beginning of year	821,556	487,019	1,308,575
NET ASSETS - end of year	\$ 595,403	\$ 533,686	\$ 1,129,089

See independent auditor's report and accompanying notes to financial statements.

**CUTANEOUS LYMPHOMA FOUNDATION, INC.
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2023**

	Net assets without restrictions	Net assets with restrictions	Total
SUPPORT AND REVENUE			
Contributions and grants	\$ 213,360	\$ 349,850	\$ 563,210
Interest income	12,739	0	12,739
TOTAL SUPPORT AND REVENUE	226,099	349,850	575,949
NET ASSETS RELEASED FROM RESTRICTIONS	673,766	(673,766)	0
	899,865	(323,916)	575,949
FUNCTIONAL EXPENSES			
Program	780,851	0	780,851
Management and general	135,994	0	135,994
Fundraising	41,189	0	41,189
TOTAL FUNCTIONAL EXPENSES	958,034	0	958,034
CHANGE IN NET ASSETS	(58,169)	(323,916)	(382,085)
NET ASSETS - beginning of year	879,725	810,935	1,690,660
NET ASSETS - end of year	\$ 821,556	\$ 487,019	\$ 1,308,575

See independent auditor's report and accompanying notes to financial statements.

**CUTANEOUS LYMPHOMA FOUNDATION, INC.
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2024 & 2023**

CASH FLOWS FROM OPERATING ACTIVITIES	<u>2024</u>	<u>2023</u>
Change in net assets from operations without restrictions	\$ (226,153)	\$ (58,169)
Adjustments to reconcile change in net assets to net cash flows from operating activities		
Depreciation	19,026	25,743
(Increase) / decrease in operating assets:		
Promises to give	(23,155)	(38,000)
Prepaid expenses / Security deposits	(9,303)	17,801
Increase / (decrease) in operating liabilities:		
Accounts payable	(4,384)	17,575
Accrued expenses	<u>0</u>	<u>0</u>
NET CASH PROVIDED BY OPERATING ACTIVITIES	(243,969)	(35,050)
CASH FLOWS FROM INVESTING ACTIVITIES		
Fixed asset purchases	<u>0</u>	<u>(10,905)</u>
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	0	(10,905)
CASH FLOWS FROM FINANCING ACTIVITIES		
Increase / (decrease) in restricted funds	<u>46,667</u>	<u>(323,916)</u>
NET CASH PROVIDED BY FINANCING ACTIVITIES	46,667	(323,916)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	(197,302)	(369,871)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	<u>1,188,789</u>	<u>1,558,660</u>
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ <u>991,487</u>	\$ <u>1,188,789</u>

See independent auditor's report and accompanying notes to financial statements.

**CUTANEOUS LYMPHOMA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2024
WITH COMPARATIVE TOTALS FOR 2023**

	2024				2023
	Program	Management and General	Fundraising	Total	Total
Research grant expense	\$ 4,500	\$ 0	\$ 0	\$ 4,500	\$ 90,500
Officer compensation	192,150	23,400	18,450	234,000	238,743
Other compensation	149,179	59,971	6,896	216,046	187,533
Payroll taxes, benefits & fees	68,735	8,592	8,592	85,919	46,939
Professional fees	56,685	6,785	914	64,384	55,023
Occupancy	17,018	3,191	1,064	21,273	20,294
Insurance	0	3,072	0	3,072	3,482
Supplies and office expense	0	0	0	0	4,796
Telephone expense	3,253	566	189	4,008	5,942
Postage, shipping & printing	43,450	2,270	3,322	49,042	49,521
Conferences, forums & travel	189,395	9,968	0	199,363	194,381
Dues and subscriptions	599	1,395	0	1,994	4,656
Computer services	15,576	1,322	572	17,470	27,416
Licenses and fees	0	1,908	3,619	5,527	3,065
Depreciation	19,026	0	0	19,026	25,743
TOTAL EXPENSES	\$ 759,566	\$ 122,440	\$ 43,618	\$ 925,624	\$ 958,034

See independent auditor's report and accompanying notes to financial statements.

NOTES TO FINANCIAL STATEMENTS

CUTANEOUS LYMPHOMA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of Cutaneous Lymphoma Foundation, Inc. is presented to assist in understanding the Organization's financial statements. The financial statements and notes are representations of the Organization's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Nature of Program

Cutaneous Lymphoma Foundation, Inc. (hereinafter called the Foundation), was established and became operational in 1998. The Foundation is an independent, not-for-profit patient advocacy organization dedicated to supporting patients with cutaneous lymphomas by promoting awareness and education, advancing patient care, and facilitating research. The Foundation is exempt from Federal income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code. The Foundation's primary sources of revenue are grants and contributions.

Basis of Accounting

The Foundation follows the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Accordingly, actual results could differ from those estimates.

Promises to Give

Promises to give are recorded as a receivable when all conditions are met. Unconditional promises to give due in the next year are recorded at net realizable value. Unconditional promises to give due after one year are recorded at the present value of their net realizable value. Conditional promises to give are recognized only when the conditions on which they depend are substantially met and the promise becomes unconditional. All promises to give recorded on statement of financial position were received within one year. There were promises to give in the amount of \$126,197 recorded on the financial statements for the current fiscal year end of June 30, 2024.

CUTANEOUS LYMPHOMA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Cash and Cash Equivalents

Cash and cash equivalents are defined as cash on hand and demand deposits in the banks plus short-term investments that are readily convertible to cash as well as investments with original maturities of three months or less.

Property & Equipment

Property and equipment purchased by the Foundation is recorded on its books at cost. Property and equipment donated to the Foundation is recorded at its estimated value at the date of receipt by the Foundation. Expenditures for major betterments and additions are charged to the property accounts, while replacements, maintenance and repairs which do not improve or extend the life of the respective assets are expensed currently.

Depreciation expense is provided under the straight-line method over three to five years depending on the type of property or equipment. Depreciation of an assets starts when it is placed into service. Gains or losses from the sale of property and equipment are recorded in the statements of activities.

Financial Statement Presentation and Contribution

The Foundation reports information regarding its financial position and activities according to two classes of net assets: net assets with restrictions and net assets without restrictions. Accordingly, contributions received are recorded as net assets with restrictions and net assets without restrictions depending on the existence and/or nature or any donor restrictions. Support that is restricted by the donor is reported as an increase in net assets without restrictions if the restriction expires or is satisfied in the reporting period in which the support is recognized. All other donor restricted support is reported as an increase in net assets with restrictions depending on the nature of the restriction. When a restriction expires or is satisfied, temporarily restricted net assets are reclassified to net assets without restrictions.

Donated Goods and Services

Donated goods and services are reflected as revenue and expense in the period received at their estimated values on the date or receipt. In addition, a number of professional and non-professional volunteers have donated hours of their time to the Foundation's programs. No value for these donated services is reflected in the accompanying financial statements because they have not met the criteria to be recorded.

CUTANEOUS LYMPHOMA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Functional Allocation of Expenses

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among programs, management and general, and fundraising on various bases and estimates. Although the methods of allocation used are considered appropriate, other methods could be used that would produce different results.

Income Taxes

The Foundation is a non-profit organization exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code and, therefore, is not subject to income tax on income derived from its exempt function.

Events Occurring After Reporting Date

The Foundation has evaluated events and transactions for potential recognition or disclosure through October 8, 2024, the date the financial statements were available to be issued.

NOTE 2 - CREDIT RISK

The Foundation maintains cash and cash equivalents at four financial locations in Michigan. Each institution is insured by the Federal Deposit Insurance Corporation with a \$250,000 limit coverage on cash accounts. Cash and cash equivalents exceeded the coverage limit as of June 30, 2024, by \$176,865. The Foundation's management does not believe it is exposed to any significant credit risks in cash and cash equivalents. The Foundation has enough cash to cover its medium-term requirements.

NOTE 3 - MAJOR CONTRIBUTORS

Support from fourteen organizations and individuals amounted to 72% of total support and revenue for the year ended June 30, 2024. Loss of such support could have a significant impact on the Foundation's activities. Management is making efforts to reduce the concentration of its revenue and support by developing the donor base.

CUTANEOUS LYMPHOMA FOUNDATION, INC.
 NOTES TO FINANCIAL STATEMENTS
 AS OF JUNE 30, 2024 & 2023

NOTE 4 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	<u>2024</u>	<u>2023</u>
Furniture and equipment	\$ 14,770	\$ 14,770
Right of Use Asset	57,624	75,961
Website	136,181	136,181
Total property and equipment	208,575	226,912
Less: accumulated depreciation	134,940	115,914
Total net property and equipment	<u>\$ 73,635</u>	<u>\$ 110,998</u>

NOTE 5 - NET ASSETS WITH RESTRICTIONS

Net assets with restrictions consisted of the following:

	<u>2024</u>	<u>2023</u>
Education, patient forums, and publications	\$ 384,125	\$ 332,958
Research	149,561	154,061
Total net assets with restrictions	<u>\$ 533,686</u>	<u>\$ 487,019</u>

Net assets were released from restrictions during the year ended June 30, by incurring expenses satisfying the purpose or time restrictions specified by donors as follows:

	<u>2024</u>	<u>2023</u>
Education, patient forums, and publications	\$ 437,303	\$ 583,266
Research related expenses	4,500	90,500
Total release of net assets with restrictions	<u>\$ 441,803</u>	<u>\$ 673,766</u>

NOTE 6 - CASH AND CASH EQUIVALENTS

Cash and cash equivalents consisted of the following at June 30:

	<u>2024</u>	<u>2023</u>
Checking accounts	\$ 80,256	\$ 206,328
Savings accounts and CDs	911,231	982,461
Total	<u>\$ 991,487</u>	<u>\$ 1,188,789</u>

CUTANEOUS LYMPHOMA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023

NOTE 7 - LEASE COMMITMENTS

The Foundation leases office space under a five-year lease which began June 1, 2022, and continuing through May 31, 2027. Rent expense was \$21,273 and \$18,099 for the years ending June 30, 2024 and 2023, respectively.

Future minimum lease payments for the years ending June 30 are as follows:

2025	\$19,069
2026	\$19,800
2027	\$18,755

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)." The Foundation has an operating lease for building rent. For fiscal years starting after December 15, 2021, The Foundation will be required to record a "right of use" asset and a lease liability which represents the amount still owed as of date of the financial statements (June 30, 2024). The asset and lease liability amounts will reduce against each other during the life of the lease.

NOTE 8 - BENEFIT PLAN PARTICIPATION

The Foundation is a participant in a multiple employer 401(k) Plan of the professional employer organization which also provides the staffing for the Foundation. Staff who are over the age of 21 are eligible to participate. The plan allows for elective matching contributions by the Foundation. Total contributions by the Foundation amounted to \$43,908 and \$38,544 during the year ended June 30, 2024 and 2023, respectively.